Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific MeetingBusiness Wire • 11/07/22
Teva Pharmaceutical Industries Limited (TEVA) Q3 2022Earnings Call TranscriptSeeking Alpha • 11/03/22
New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisisCNN Business • 11/03/22
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFCBusiness Wire • 10/25/22
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's DiseaseBusiness Wire • 10/18/22
Teva Reaches Agreement With Arkansas to Settle the State's Price Fixing ClaimsBusiness Wire • 10/07/22
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022Business Wire • 10/06/22
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related OutcomesBusiness Wire • 10/06/22
Teva Reaches Agreement With Georgia to Settle the State's Price Fixing ClaimsBusiness Wire • 09/30/22
Teva Launches Honestly HD Website to Provide People Living With Huntington's Disease (HD) Information, Inspiration and Resources on HD ChoreaBusiness Wire • 09/26/22